Intellia Therapeutics Inc Stock News

Gene-editing stocks have sunk under the weight of rising interest rates and high inflation. These macroeconomic headwinds, however, may be creating a once-in-a-lifetime buying opportunity.

Intellia is advancing gene-editing candidates for diseases with limited treatment options. Invitae is making progress on a plan to speed up the timeline to positive cash flow.

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies lever

Cathie Wood's Ark Invest ETFs added to their positions recently in two biotech stocks and one telehealth stock. All three stocks have plunged over the past couple of years.

Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Let's find out.

The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend

Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communication

Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring rad

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics

Intellia Therapeutics: Signs Of Possible Life.

Many investors look for growth opportunities wherever they can find them. If that describes you, then there are some high-growth biotech stocks that could present an opportunity.

Intellia Therapeutics is a gene-editing company with lots of potential if it can get an approved treatment or therapy. Rivian Automotive plans to double its production in 2023 as its business generate

Against the backdrop of a solid day on Wall Street, CRISPR Therapeutics (NASDAQ: CRSP ) distinguished itself, popping up nearly 16%. The catalyst appears to center on CRISPR's single-dose therapy for

Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attr